<DOC>
	<DOCNO>NCT00527930</DOCNO>
	<brief_summary>Phase II trial oxaliplatin combination S-1 ( SOX ) patient recurrent metastatic breast cancer ( MBC ) previously treat resistant anthracycline taxane</brief_summary>
	<brief_title>Phase II Trial Oxaliplatin Combination With S-1 ( SOX ) Patients With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>The main purpose study find efficacy safety profile TS-1 oxaliplatin previously anthracycline taxane pretreated patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>M/F age ≥ 18 Metastatic ( TxNxM1 ) inoperable locally recurrent breast cancer ( rT4NxM0 ) taxane &amp; anthracycline therapy Measurable disease ( RECIST ) : A patient least one measurable lesion diameter confirm 10mm spiral CT multidetector CT ( MD CT ) , 20 mm longer conventional CT No prior treatment S1 , capecitabine , platinum In metastatic setting Must receive anthracycline taxane adj . metastatic setting ( concurrent , sequential , combine drug ) For taxanes ( Paclitaxel ( P ) / Docetaxel ( D ) ) 1 . Must progress receive P D ( Patients relapse within 12 month complete adjuvant chemotherapy contain anthracycline taxane , require prior chemotherapy metastatic disease ) 2 . Only 1 adjuvant regimen permit ( neoadjuvant immediately follow surgery immediately follow adj . permit ) For anthracyclines 1 . Progressed anthracycline treatment , without initial response 2 . Have receive adequate course anthracyclines define follow : 1 . Adj . : Must receive standard regimen ( doxorubicin ≥ 240 mg/m2 ≥ 360 mg/m2 epirubicin equivalent ) 2 . Metastatic : Must receive standard regimen ( doxorubicin ≥300mg/m2 equivalent ) Not candidate Herceptin ECOG PS ≤ 2 Completion prior chemotherapy ≥ 3 wks prior enrol Completion hormonal therapy 2 wks prior enroll Resolution clinically significant toxic effect ( exclude alopecia sensory neuropathy ) prior surgery therapy grade ≤ 1 ( NCI CTCAE 3.0 ) , peripheral neuropathy grade ≤ 2 ( NCI CTCAE 3.0 ) , within limit list specific inclusion/exclusion criterion A patient willingness comply study protocol study period capable complying . Informed consent obtain . WOCBP ( woman child bear potential ) unwilling use acceptable method avoid pregnancy Breast feeding pregnant woman Patients Hx symptomatic brain leptomeningeal involvement ( eligible asymptomatic 2weeks proper radiation therapy ) ≥grade 3 neuropathy currently Hx second malignancy except adequately treat basal squamous skin ca CIS cervix . Adequately treated contralateral breast ca DF &gt; 5 yr prior study permit MI , unstable angina , CABG , clinically significant arrhythmia within 6 mo Hx inflammatory bowel disease chronic diarrhea , ANC &lt; 1500 , Plt &lt; 100K , Hb &lt; 9.0 Ccr &lt; 60 ml/min creatinine &gt; 1.5 Bil &gt; 1.5 x UNL , AST/ALT ≥ 2.5xUNL hepatic meta + &gt; 5xUNL ) History hypersensitivity 5FU , platinum , compound similar chemical structure More 3 prior chemotherapy metastatic recurrent disease prior treatment S1 , capecitabine platinum analog metastatic setting ( 5FU combine agent metastatic setting allowed_ ex ) CMF , FAC ) Her2 ( + ) pts candidate Herceptin prior surgery within 4 week participate clinical trial within 4 week prior radiation therapy within 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>S1</keyword>
</DOC>